Sinotherapeutics (SH:688247) Zheng Quan Zhi Xing·2025-07-14 16:28Core Viewpoint - The major shareholder of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. plans to reduce its shareholding due to operational needs, with a maximum reduction of 7,000,000 shares, accounting for no more than 1.5441% of the total share capital [1][2]. Group 1: Major Shareholder Information - The major shareholder, Nanjing Qihe Venture Capital Partnership (Limited Partnership), holds 25,798,000 shares, representing 5.6907% of the total share capital [1][2]. - The shares held by the major shareholder were acquired prior to the company's initial public offering (IPO) and were released from restrictions on August 25, 2023 [1][2]. Group 2: Reduction Plan Details - The reduction plan involves a maximum of 7,000,000 shares, with a breakdown of up to 4,500,000 shares through centralized bidding and up to 2,500,000 shares through block trading [2]. - The reduction period for centralized bidding is set for three months starting 15 trading days after the announcement date, while the block trading will follow the same timeline [1][2]. Group 3: Compliance and Commitments - The major shareholder has previously committed to not transferring or managing the shares held prior to the IPO for 36 months and has set limits on the amount of shares that can be sold within specific time frames [4][5]. - The company confirms that the current reduction plan aligns with previously disclosed commitments and does not violate any regulations [5].